# Palifermin After Haploidentical PBSCT

> **NCT00570999** · PHASE2 · WITHDRAWN · sponsor: **European Society for Blood and Marrow Transplantation**

## Conditions studied

- Non-Hodgkin's Lymphoma or Hodgkin's Disease
- Acute Leukaemia
- Myelodysplastic Syndrome
- Chronic Myeloid Leukemia
- Osteomyelofibrosis

## Interventions

- **DRUG:** Palifermin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00570999
- **Lead sponsor:** European Society for Blood and Marrow Transplantation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-02
- **Primary completion:** —
- **Final completion:** 2013-01
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00570999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00570999, "Palifermin After Haploidentical PBSCT". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00570999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*